Primary regulatory
FDA MedWatch: Safety Information and Adverse Event Reporting Program
FDA's MedWatch program for reporting adverse events, product quality problems, and medication errors related to FDA-regulated products including compounded drugs. Voluntary for consumers, mandatory for certain healthcare entities. There is no equivalent reporting system for RUO-sourced products.
U.S. Food and Drug AdministrationPublished Jul 8, 2026Accessed Jul 8, 2026
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-medwatch
Source usage
Linked from 9 pages
Guide
Compounded GLP-1 Regulation: What Changed and What to Check
GuideFDA Warning Letter Tracker: Enforcement Actions Against Peptide Sellers
Research hubCommunity Guidelines: What's Allowed and Not Allowed in Peptide Discussions
Research hubCompounded Peptides Explained: 503A vs 503B
Research hubPeptide Community Hub: Reddit, YouTube, Telegram, and Discord Spaces
Research hubRUO Marketplace Risk Guide: How to Evaluate Marketplace Risk Without Buying
Research hubRUO vs Telehealth: How People Access Peptides
Research hubUser-Submitted Supplier Reviews: A Moderated Framework for Sharing Supplier Documentation Experiences
Research hubWhat Does 'Research Use Only' Actually Mean?
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.